Otubain 2 promotes muramyl dipeptide-mediated anti-colitogenic effects due to de-ubiquitination of receptor interaction protein 2

Jochen Mattner

doi:10.1002/ctd2.70014

Clinical and Translational Discovery ›› 2024, Vol. 4 ›› Issue (5) : e70014 DOI: 10.1002/ctd2.70014

COMMENTARY

Otubain 2 promotes muramyl dipeptide-mediated anti-colitogenic effects due to de-ubiquitination of receptor interaction protein 2

Jochen Mattner ¹^,²^,^†

Author information +

History +

PDF

Cite this article

Download citation ▾

Jochen Mattner. Otubain 2 promotes muramyl dipeptide-mediated anti-colitogenic effects due to de-ubiquitination of receptor interaction protein 2. Clinical and Translational Discovery, 2024, 4(5): e70014 DOI:10.1002/ctd2.70014

登录浏览全文

4963

注册一个新账户忘记密码

References

Publishing order | Descend order by publishing year | Descend order by cited within

[1]	DuX, XuJ, MeiF, et al. Deubiquitination of RIPK2 by OTUB2 augments NOD2 signalling and protective effects in intestinal inflammation. Clin Transl Med. 2024;14:e70038.

[2]	PhilpottDJ, Sorbara MT, RobertsonSJ, et al. NOD proteins: regulators of inflammation in health and disease. Nat Rev Immunol. 2014;14:9-23.

[3]	LiuZ, ZhangY, JinT, et al. The role of NOD2 in intestinal immune response and microbiota modulation: a therapeutic target in inflammatory bowel disease. Int Immunopharmacol. 2022;113:109466.

[4]	Kaczmarek-RysM, Hryhorowicz ST, LisE, et al. Crohn’s disease susceptibility and onset are strongly related to three NOD2 gene haplotypes. J Clin Med. 2021;10.

[5]	van HeelDA, GhoshS, ButlerM, et al. Muramyl dipeptide and toll-like receptor sensitivity in NOD2-associated Crohn’s disease. Lancet. 2005;365:1794-1796.

[6]	BonenDK, OguraY, NicolaeDL, et al. Crohn’s disease-associated NOD2 variants share a signalling defect in response to lipopolysaccharide and peptidoglycan. Gastroenterology. 2003;124:140-146.

[7]	WatanabeT, AsanoN, MurrayPJ, et al. Muramyl dipeptide activation of nucleotide-binding oligomerization domain 2 protects mice from experimental colitis. J Clin Invest. 2008;118:545-559.

[8]	ShenJ, LouL, DuX, et al. YOD1 sustains NOD2-mediated protective signalling in colitis by stabilizing RIPK2. EMBO Rep. 2024.

[9]	DikicI, Schulman BA. An expanded lexicon for the ubiquitin code. Nat Rev Mol Cell Biol. 2023;24:273-287.

[10]	RuanJ, Schluter D, NaumannM, et al. Ubiquitin-modifying enzymes as regulators of colitis. Trends Mol Med. 2022;28:304-318.

[11]	LiJ, ZhangN, LiM, et al. The emerging role of OTUB2 in diseases: from cell signaling pathway to physiological function. Front Cell Dev Biol. 2022;10:820781.

RIGHTS & PERMISSIONS

2024 The Author(s). Clinical and Translational Discovery published by John Wiley & Sons Australia, Ltd on behalf of Shanghai Institute of Clinical Bioinformatics.